Could cause temporary or reversible harm; serious harm is unlikely.
CGMP Deviations: Intermittent exposure to temperature excursion during storage.
| Brand name | XIGDUO |
| Generic name | DAPAGLIFLOZIN AND METFORMIN HYDROCHLORIDE |
| Active ingredient(s) | DAPAGLIFLOZIN PROPANEDIOL, METFORMIN HYDROCHLORIDE |
| Distributed by / for | AstraZeneca Pharmaceuticals LP Wilmington, DE 19850 |
| NDC | 0310-6280-30 |
| Full product label | xigduo XR (dapgliflozin/metformin HCl extended-release) tablets 10 mg/1000 mg 30 Tablets Rx only NDC 0310-6280-30 Manufactured for: AstraZeneca Pharmaceuticals LP Wilmington, DE 19850 Manufactured by: Bristol-Myers Squibb Manufacturing Company Humacao, Puerto Rico 00791 |
| Recalling firm | Cardinal Health Inc. |
| Distribution | FL, GA, SC |
| Quantity | 664 bottles |
| Recall initiated | 2021-03-15 |
| Report date | 2021-06-02 |
| Recall completed | 2024-06-17 |
| Recall number | D-0435-2021 |
| Classification | Class II |
| FDA status | Terminated |
| Origin on file | Dublin OH United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗